



Immunogenic Cell Death and Associated Antitumor Immunity

Guest Editor:

Prof. Dr. Steven Fiering

1. Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA
2. Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA

Deadline for manuscript submissions:

closed (15 May 2024)

Message from the Guest Editor

Dear Colleagues,

Roughly 20 years ago, studies by Zitvogel, Kroemer, and their colleagues showed that some commonly used cytotoxic cancer drugs were stimulating antitumor immune responses against tumors, which were important in those drugs' treatment efficacy. This generated the concept of "immunogenic cell death" (ICD) and added "death-associated molecular patterns" (DAMPs) as additional immunogenic signals to "pathogen-associated molecular patterns" (PAMPs). How ICD, caused by cytotoxic chemotherapy or other cancer treatments such as radiation or heat, interacts with the immune system is still an important topic of active research.

This Special Issue is designed to assemble important work in the area of ICD due to cancer therapy, how it interacts with natural or treatment-generated antitumor immunity, and how that response can be further strengthened to improve outcomes for patients

Prof. Dr. Steven Fiering
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)